Electromed (ELMD) Q1 2025 earnings summary

Executive summary

• Achieved eighth consecutive quarter of year-over-year revenue and profit growth, with net revenue of $14.7 million, up 19% year-over-year, and net income rising to $1.5 million ($0.16 per diluted share) from $0.2 million ($0.02 per diluted share) year-over-year.

• Operating income reached $1.9 million, a significant increase from $0.1 million in the prior year, as revenue growth outpaced expense increases.

• Gross profit margin improved to 78.3% from 77.1% year-over-year, supported by higher average net revenue per device.

• Strategic focus on expanding sales team, direct-to-consumer investments, and launching the "Triple Down on Bronchiectasis" campaign to drive growth.

• Repurchased 262,756 shares for $4.54 million, nearing the $5 million authorization.

Financial highlights

• Net revenue grew 19% year-over-year to $14.7 million; home care revenue rose 18.5% to $13.2 million, and hospital revenue increased 36.1% to $690,000.

• Gross profit was $11.5 million (78.3% of net revenues), up from $9.5 million (77.1%) in the prior year.

• Operating income was $1.9 million (13.2% of revenue), up from $0.1 million (1.2%) last year.

• Net income reached $1.5 million; pre-tax income was $2.1 million; diluted EPS was $0.16, up from $0.02 in the prior year.

• Cash and cash equivalents stood at $13.9 million as of quarter end.

Outlook and guidance

• Management expects double-digit top-line growth and expanded operating leverage for the full year, with current working capital and available credit sufficient for operational and capital needs.

• Continued focus on sales force expansion, direct-to-consumer efforts, and payer relations to drive future growth.

• Macroeconomic factors such as inflation are being monitored, but liquidity is expected to remain adequate.